ALPCO’s automated turbidimetric solution for calprotectin testing offers enhanced efficiency without compromising clinical sensitivity or specificity. Clinicians can prioritize endoscopic evaluation for the patients that need it most and quickly put IBS patients on the right treatment path. 

Join our speaker from Department of Pathology , University of Utah School of Medicine, Dr. Heather Nelson, to discuss how to validate and launch a FDA-approved assay.

ALPCO offers targeted GI solutions suitable for all types of labs. Our offerings range from plate-based to clinical chemistry analyzer-based and automated flash chemiluminescence solutions, all designed to accommodate your lab’s expanding testing needs and capabilities.

In the webinar, Dr. Benjamin Click from the University of Colorado, Department of Gastroenterology, underscores the critical role of non-invasive monitoring methods, particularly fecal calprotectin monitoring, in guiding treatment adjustments and achieving therapeutic goals..

This infographic distills the essence of the new American Gastroenterological Association (AGA) Clinical Practice Guideline on the Role of Biomarkers in Crohn's Disease (CD). It sheds light on the nuanced recommendations for using biomarkers to monitor and evaluate CD, emphasizing their value in conjunction with clinical symptoms. 

In an effort to improve patient care, an increasing number of gastroenterologists are using fecal calprotectin levels as a first step in the diagnosis of IBD versus IBS. ALPCO tests enable clinicians to accurately assess patients via calprotectin and quickly start patients on the right treatment path.

Reduce False Positives from 26% to 7%! An increase in clinical specificity, and a decrease in false positives, enables clinicians to better evaluate IBD/IBS patients. Clinicians can schedule follow-up colonoscopies for the patients that need it most and start IBS patients on the right treatment path.

For laboratories with a compatible clinical chemistry analyzer, upgrading to the calprotectin immunoturbidimetric assay can improve efficiency and generate additional capacity. Laboratories can potentially eliminate a CLIA system or simply create new capacity on that system by transferring calprotectin to another analyzer.

Test results from outside laboratories can sometimes take up to 5 days. Random access testing enables laboratories to offer affordable same-day results. On-site testing eliminates the shipping process and maintains remnant samples on-site.

Maximize lab efficiency with ALPCO's calprotectin immunoturbidimetric assay. Leverage existing analyzers, ensure accurate results, and improve turnaround times.